{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:16:12Z","timestamp":1775888172541,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CENTRO-01-0145-FEDER-030752"],"award-info":[{"award-number":["CENTRO-01-0145-FEDER-030752"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-030478"],"award-info":[{"award-number":["POCI-01-0145-FEDER-030478"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.phrs.2020.105267","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T03:18:11Z","timestamp":1603768691000},"page":"105267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Cystic fibrosis: Physiopathology and the latest pharmacological treatments"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3320-9658","authenticated-orcid":false,"given":"Carla","family":"Fonseca","sequence":"first","affiliation":[]},{"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[]},{"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3854-6549","authenticated-orcid":false,"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105267_bib0005","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3389\/fphar.2018.01113","article-title":"Emerging microRNA therapeutic approaches for cystic fibrosis","volume":"9","author":"Bardin","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2020.105267_bib0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1164\/rccm.19612P23","article-title":"Twenty facts about cystic fibrosis","volume":"196","author":"Sockrider","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2020.105267_bib0015","doi-asserted-by":"crossref","first-page":"16083","DOI":"10.3390\/ijms150916083","article-title":"Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications","volume":"15","author":"Seegmiller","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2020.105267_bib0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.phrs.2020.105267_bib0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1085\/jgp.201711946","article-title":"Structural mechanisms of CFTR function and dysfunction","volume":"150","author":"Hwang","year":"2018","journal-title":"J. Gen. Physiol."},{"issue":"8","key":"10.1016\/j.phrs.2020.105267_bib0030","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.phrs.2020.105267_bib0035","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/path.5095","article-title":"Small RNA and transcriptome sequencing reveal the role of miR-199a-3p in inflammatory processes in cystic fibrosis airways","volume":"245","author":"Bardin","year":"2018","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.phrs.2020.105267_bib0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/MED.0000000000000439","article-title":"Updates in vitamin D therapy in cystic fibrosis","volume":"25","author":"Le","year":"2018","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"6","key":"10.1016\/j.phrs.2020.105267_bib0045","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1016\/j.lpm.2017.05.011","article-title":"Current and emerging cormobidities in cystic fibrosis","volume":"46","author":"Ronan","year":"2017","journal-title":"La Presse M\u00e9dicale"},{"issue":"6","key":"10.1016\/j.phrs.2020.105267_bib0050","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.lpm.2017.01.024","article-title":"New treatments targeting the basic defects in cystic fibrosis","volume":"46","author":"Fajac","year":"2017","journal-title":"La Presse M\u00e9dicale"},{"issue":"10059","key":"10.1016\/j.phrs.2020.105267_bib0055","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2020.105267_bib0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1183\/09031936.00196314","article-title":"Future trends in cystic fibrosis demography in 34 European countries","volume":"46","author":"Burgel","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.phrs.2020.105267_bib0065","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMc1916747","article-title":"Triple therapy for cystic fibrosis with a Phe508del CFTR mutation","volume":"382","author":"Jain","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2020.105267_bib0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"De Boeck","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"13","key":"10.1016\/j.phrs.2020.105267_bib0075","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2217\/pgs.16.25","article-title":"Pharmacogenetics of cystic fibrosis treatment","volume":"17","author":"Carter","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2020.105267_bib0080","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/ppul.23247","article-title":"CFTR, bicarbonate, and the pathophysiology of cystic fibrosis","volume":"50","author":"Borowitz","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.phrs.2020.105267_bib0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Saint-Criq","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"issue":"11","key":"10.1016\/j.phrs.2020.105267_bib0090","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1113\/JP271311","article-title":"Pore dilatation increases the bicarbonate permeability of CFTR, ANO1 and glycine receptor anion channels","volume":"594","author":"Jun","year":"2016","journal-title":"J. Physiol."},{"issue":"20","key":"10.1016\/j.phrs.2020.105267_bib0095","first-page":"1","article-title":"Adapting proteostasis and autophagy for controlling the pathogenesis of cystic fibrosis lung disease","volume":"10","author":"Bodas","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2020.105267_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/genes11050546","article-title":"Transcriptomic and proteostasis networks of CFTR and the development of small molecule modulators for the treatment of cystic fibrosis lung disease","volume":"11","author":"Strub","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.phrs.2020.105267_bib0105","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1111\/febs.12457","article-title":"CFTR: a hub for kinase and crosstalk of cAMP and Ca2+","volume":"280","author":"Kunzelmann","year":"2013","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.phrs.2020.105267_bib0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ismej.2011.83","article-title":"Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection","volume":"6","author":"Hansen","year":"2011","journal-title":"ISME J."},{"issue":"2","key":"10.1016\/j.phrs.2020.105267_bib0115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1378\/chest.128.2.729","article-title":"Massive hemoptysis in cystic fibrosis","volume":"128","author":"Flume","year":"2005","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.phrs.2020.105267_bib0120","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1378\/chest.128.2.720","article-title":"Pneumothorax in cystic fibrosis","volume":"128","author":"Flume","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.phrs.2020.105267_bib0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MPG.0b013e3181a6e01d","article-title":"Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS","volume":"50","author":"Houwen","year":"2010","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105267_bib0130","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1194\/jlr.M050369","article-title":"Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase","volume":"55","author":"Umunakwe","year":"2014","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.phrs.2020.105267_bib0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/GCO.0b013e32835f1745","article-title":"Cystic fibrosis and fertility","volume":"25","author":"Ahmad","year":"2013","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.phrs.2020.105267_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1753466619844424","article-title":"The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy","volume":"13","author":"Lommatzsch","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.phrs.2020.105267_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/4803974","article-title":"Osteoporosis Is Associated with Deteriorating Clinical Status in Adults with Cystic Fibrosis","volume":"2018","author":"Mathiesen","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.phrs.2020.105267_bib0150","series-title":"2018 Patient Registry, Annual Data Report","author":"Cystic Fibrosis Foundation","year":"2019"},{"issue":"6","key":"10.1016\/j.phrs.2020.105267_bib0155","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jpeds.2015.03.042","article-title":"New challenges in the diagnosis and management of cystic fibrosis","volume":"166","author":"Levy","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.phrs.2020.105267_bib0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pharmthera.2014.06.005","article-title":"New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls","volume":"145","author":"Bell","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2020.105267_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088567","article-title":"Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients","volume":"9","author":"Wojewodka","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.105267_bib0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpeds.2016.09.067","article-title":"Cystic fibrosis diagnostic challenges over 4 decades: historical perspectives and lessons learned","volume":"181","author":"Farrel","year":"2017","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.phrs.2020.105267_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2008.05.005","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181","author":"Farrell","year":"2017","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.phrs.2020.105267_bib0180","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MOP.0000000000000627","article-title":"Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis","volume":"30","author":"Burgener","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"issue":"3","key":"10.1016\/j.phrs.2020.105267_bib0185","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.phrs.2020.105267_bib0190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"67","author":"Clancy","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.phrs.2020.105267_bib0195","first-page":"1","article-title":"Tezacaftor for the treatment of cystic fibrosis","author":"Sala","year":"2018","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.phrs.2020.105267_bib0200","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.phrs.2020.105267_bib0205","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/apm.12915","article-title":"Cystic fibrosis - an example of personalized and precision medicine","volume":"127","author":"Skov","year":"2019","journal-title":"APMIS"},{"issue":"3","key":"10.1016\/j.phrs.2020.105267_bib0210","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105267_bib0215","article-title":"Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from Mono or dual regimens to triple-combination Elexacaftor\/Tezacaftor\/Ivacaftor","author":"Tsai","year":"2020","journal-title":"Pulm. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2020.105267_bib0220","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jcf.2013.02.007","article-title":"Tobramycin is a suppressor of premature termination codons","volume":"12","author":"Altamura","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.phrs.2020.105267_bib0225","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/cdd.2016.22","article-title":"A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR","volume":"23","author":"Tosco","year":"2016","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.phrs.2020.105267_bib0230","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/14728222.2019.1628948","article-title":"Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets","volume":"23","author":"Hanrahan","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.phrs.2020.105267_bib0235","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.coph.2017.10.006","article-title":"Genetic therapies for cystic fibrosis lung disease","volume":"34","author":"Hart","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105267_bib0240","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BST20170469","article-title":"Non-coding RNA in cystic fibrosis","volume":"46","author":"Glasgow","year":"2018","journal-title":"Biochem. Soc. Trans."},{"issue":"9","key":"10.1016\/j.phrs.2020.105267_bib0245","first-page":"684","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.phrs.2020.105267_bib0250","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1073\/pnas.1502281112","article-title":"Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy","volume":"112","author":"Mastorakos","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2020.105267_bib0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060448","article-title":"Gene mutation in MicroRNA target sites of cftr gene: a novel pathogenetic mechanism in cystic fibrosis?","volume":"8","author":"Amato","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.phrs.2020.105267_bib0260","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1183\/09031936.00113214","article-title":"Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis","volume":"45","author":"Viart","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"33","key":"10.1016\/j.phrs.2020.105267_bib0265","doi-asserted-by":"crossref","first-page":"13362","DOI":"10.1073\/pnas.1210906109","article-title":"A microRNA network regulates expression and biosynthesis of wild-type and F508 mutant cystic fibrosis transmembrane conductance regulator","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2020.105267_bib0270","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1080\/15548627.2016.1217370","article-title":"Elevated Mirc1\/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages","volume":"12","author":"Tazi","year":"2016","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.phrs.2020.105267_bib0275","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1165\/rcmb.2012-0430OC","article-title":"Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by MicroRNAs","volume":"49","author":"Ramachandran","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105267_bib0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1164\/rccm.201311-1986OC","article-title":"miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production","volume":"190","author":"Weldon","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.phrs.2020.105267_bib0285","article-title":"Pharmacological modulation of the AKT\/microRNA-199a-5p\/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation","volume":"6","author":"Zhang","year":"2015","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.phrs.2020.105267_bib0290","doi-asserted-by":"crossref","first-page":"11604","DOI":"10.1074\/jbc.M110.198390","article-title":"Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of Interleukin-8","volume":"286","author":"Bhattacharyya","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"8386","key":"10.1016\/j.phrs.2020.105267_bib0295","first-page":"1","article-title":"miR-34\/449 control apical actin network formation during multiciliogenesis through small GTPase pathways","volume":"6","author":"Chevalier","year":"2015","journal-title":"Nat. Commun."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2020.105267_bib0300","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11010-011-0975-2","article-title":"MiR-146a negatively regulates neutrophil elastase-induced MUC5AC secretion from 16HBE human bronchial epithelial cells","volume":"358","author":"Zhong","year":"2011","journal-title":"Mol. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.phrs.2020.105267_bib0305","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.4049\/jimmunol.0902669","article-title":"miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression","volume":"184","author":"Oglesby","year":"2010","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105267_bib0310","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ymthe.2020.02.001","article-title":"Precise targeting of miRNA sites restores CFTR activity in CF bronchial epithelial cells","volume":"28","author":"De Santi","year":"2020","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2020.105267_bib0315","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00813-z","article-title":"MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology","volume":"8","author":"Sonneville","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2020.105267_bib0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1042\/BJ20110672","article-title":"microRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene","volume":"438","author":"Gillen","year":"2011","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.phrs.2020.105267_bib0325","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1113\/JP277042","article-title":"Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis","volume":"597","author":"Yeh","year":"2019","journal-title":"J. Physiol. (Lond.)"},{"issue":"7","key":"10.1016\/j.phrs.2020.105267_bib0330","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.phrs.2020.105267_bib0335","first-page":"23","article-title":"Keep them breathing cystic fibrosis pathophysiology, diagnosis, and treatment","volume":"30","author":"Brown","year":"2017","journal-title":"J. Am. Acad. Physician Assist."},{"key":"10.1016\/j.phrs.2020.105267_bib0340","series-title":"Ag\u00eancia Europeia de Medicamentos, Resumo das Caracter\u00edsticas do Medicamento \u2013 Aztreonam","author":"EMA","year":"2016"},{"key":"10.1016\/j.phrs.2020.105267_bib0345","series-title":"Autoridade Nacional do Medicamento e Produtos de Sa\u00fade, I.P., Resumo das Caracter\u00edsticas do Medicamento \u2013 Tobramicina","author":"INFARMED","year":"2014"},{"key":"10.1016\/j.phrs.2020.105267_bib0350","series-title":"Autoridade Nacional do Medicamento e Produtos de Sa\u00fade, I.P., Resumo das Caracter\u00edsticas do Medicamento \u2013 Azitromicina","author":"INFARMED","year":"2018"},{"key":"10.1016\/j.phrs.2020.105267_bib0355","series-title":"Autoridade Nacional do Medicamento e Produtos de Sa\u00fade, I.P., Resumo das Caracter\u00edsticas do Medicamento \u2013 Dornase alfa","author":"INFARMED","year":"2015"},{"key":"10.1016\/j.phrs.2020.105267_bib0360","series-title":"Cystic Fibrosis Foundation, Pancreatic Enzymes Clinical Care Guidelines","author":"Schwarzenberg","year":"2019"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820315759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820315759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:12:19Z","timestamp":1760911939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820315759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":72,"alternative-id":["S1043661820315759"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105267","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic fibrosis: Physiopathology and the latest pharmacological treatments","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105267"}}